Lung Cancer Clinical Trial
Risk Stratification for Patients With Hospital-diagnosed Advanced Lung Cancer
Summary
This study explores whether supportive care interventions that might reduce rehospitalization could be implemented and feasible, in subjects within a high-risk group of subjects with newly diagnosed hospitalized advanced lung cancer (ALC).
Subjects will be considered high risk if they have small cell histology, longer than 8 days hospitalization, high comorbidity, emergency department use or hospitalization in the previous 6 months, prescription of a wheelchair on hospital discharge, or Black and/or Hispanic race. Supportive care interventions such as navigation and palliative care will be recommended for this group.
All hospitalized subjects with newly diagnosed ALC will be offered web- or telephone-based patient-reported outcome (PRO) symptom monitoring for 90 days following hospital discharge if they provide consent. Medical record evaluation of consented subjects will provide data for risk assessment and the high-risk group definition. Healthcare utilization including emergency department visits, hospitalizations, outpatient palliative care, and cancer treatment received will be compared.
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years at the time of screening.
Hospital-diagnosed Advanced lung cancer with histological confirmation of disease or suspected lung cancer in the opinion of the treating oncologist.
For PROs only 1. Able to complete a web-based or telephonic symptom survey.
Exclusion Criteria:
1. Enrollment in hospice upon discharge from the index hospitalization For PROs only
Inability to read or speak English.
Dementia, altered mental status, or any psychiatric condition as determined by the clinical or study team that would prohibit the understanding or rendering of informed consent.
Current incarceration.
Any condition that would prohibit the patient from completing PROs
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Chapel Hill North Carolina, 27599, United States More Info
Principal Investigator
How clear is this clinincal trial information?